

## LITERATURA

1. **Zowawi HM, Harris PN, Roberts MJ, et al.** The emerging threat of multidrug-resistant Gram-negative bacteria in urology. *Nat Rev Urol.* 2015; 12(10): 570–584.
2. **Bonkat G, Pickard R, Bartoletti R, et al.** EAU Guidelines on Urological Infections. European Association of Urology. 2017.
3. **Le Fanu J.** The Rise and Fall of Modern Medicine. Hachette, Londýn 2011; 13–20. ISBN 978-0-349-12375-2.
4. **Bonkat G, Müller G, Braissant O, et al.** Increasing prevalence of ciprofloxacin resistance in extended-spectrum- $\beta$ -lactamase-producing *Escherichia coli* urinary isolates. *World J Urol.* 2013; 31(6): 1427–1432.
5. **Fajfr M, Louda M, Paterová P, et al.** The susceptibility to fosfomycin of Gram-negative bacteria isolates from urinary tract infection in the Czech Republic: data from a unicentric study. *BMC Urol.* 2017; 26; 17(1): 33.
6. **Magyar A, Köves B, Nagy K, et al.** Spectrum and antibiotic resistance of uropathogens between 2004 and 2015 in a tertiary care hospital in Hungary. *J Med Microbiol.* 2017; 66(6): 788–797.
7. **Toner L, Papa N, Aliyu SH, et al.** Extended-spectrum beta-lactamase-producing Enterobacteriaceae in hospital urinary tract infections: incidence and antibiotic susceptibility profile over 9 years. *World J Urol.* 2016; 34(7): 1031–1037.
8. **Sbiti M, Lahmadi K, Louzi L.** Epidemiological profile of uropathogenic enterobacteria producing extended spectrum beta-lactamases]. *Pan Afr Med J.* 2017; 13: 28–29.
9. **Girometti N, Lewis RE, Giannella M, et al.** Klebsiella pneumoniae bloodstream infection: epidemiology and impact of inappropriate empirical therapy. *Medicine (Baltimore)* 2014; 93(17): 298–309.
10. **Cho YH, Jung SI, Chung HS, et al.** Antimicrobial susceptibilities of extended-spectrum beta-lactamase-producing *Escherichia coli* and *Klebsiella pneumoniae* in health care-associated urinary tract infection: focus on susceptibility to fosfomycin. *Int Urol Nephrol.* 2015; 47(7): 1059–1066.
11. **Concia E, Azzini AM.** Aetiology and antibiotic resistance issues regarding urological procedures. *J Chemother.* 2014; 26Suppl 1: S14–23.
12. **Vallée M, Bruyère F, Roblot F, Brureau L.** Temocillin and urinary tract infections. *Prog Urol.* 2017; 27(12): 609–617.
13. **Wagenlehner FM, Alidjanov JF.** Efficacy, pharmacokinetic and pharmacodynamics profile of ceftolozane + tazobactam in the treatment of complicated urinary tract infections. *Expert Opin Drug MetabToxicol.* 2016; 12(8): 959–966.
14. **Stapleton PJ, Landon DJ, McWade R, et al.** Antibiotic resistance patterns of *Escherichia coli* urinary isolates and comparison with antibiotic consumption data over 10 years, 2005–2014. *Ir J Med Sci.* 2017; 186(3): 733–741.
15. **Jiménez-Alcaide E, Medina-Polo J, García-González L, et al.** Healthcare-associated urinary tract infections in patients with a urinary catheter: Risk factors, microbiological characteristics and patterns of antibiotic resistance]. *Arch Esp Urol.* 2015; 68(6): 541–550.
16. **Černohorská L, Sláviková P.** Pseudomonas aeruginosa, její rezistence k vybraným antibiotikům a tvorba biofilmu u kmenů izolovaných od pacientůs infekcí močových cest. *Epidemiol Mikrobiol Imunol.* 2009; 58(4): 154–157.
17. **Toner L, Papa N, Aliyu SH, et al.** Vancomycin resistant enterococci in urine cultures: Antibiotic susceptibility trends over a decade at a tertiary hospital in the United Kingdom. *Investig Clin Urol.* 2016; 57(2): 129–134.
18. **Lara-Isla A, Medina-Polo J, Alonso-Isa M, et al.** Urinary Infections in Patients with Catheters in the Upper Urinary Tract: Microbiological Study. *Urol Int.* 2017; 98(4): 442–448.
19. **Cai T, Mazzoli S, Lanzafame P et al.** Asymptomatic bacteriuria in Clinical Urological Practice: Preoperative Control of Bacteriuria and Management of Recurrent UTI. *Pathogens* 2016; 5: 4. doi: 10.3390/pathogens5010004.
20. **Routh JC, Alt AL, Ashley RA, Kramer SA, Boyce TG.** Increasing prevalence and associated risk factors for methicillin resistant *Staphylococcus aureus* bacteriuria. *J Urol.* 2009; 181(4): 1694–1698.